Last reviewed · How we verify
CJ-40010 Bivalent vaccine E dose — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
CJ-40010 Bivalent vaccine E dose (CJ-40010 Bivalent vaccine E dose) — HK inno.N Corporation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CJ-40010 Bivalent vaccine E dose TARGET | CJ-40010 Bivalent vaccine E dose | HK inno.N Corporation | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CJ-40010 Bivalent vaccine E dose CI watch — RSS
- CJ-40010 Bivalent vaccine E dose CI watch — Atom
- CJ-40010 Bivalent vaccine E dose CI watch — JSON
- CJ-40010 Bivalent vaccine E dose alone — RSS
Cite this brief
Drug Landscape (2026). CJ-40010 Bivalent vaccine E dose — Competitive Intelligence Brief. https://druglandscape.com/ci/cj-40010-bivalent-vaccine-e-dose. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab